Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Brand names: TRODELVY
12.1 Mechanism of Action Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate. Sacituzumab is a humanized antibody that recognizes Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a linker. Pharmacology data suggest that sacituzumab govitecan-hziy binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and cell death. Sacituzumab govitecan-hziy decreased tumor growth in mouse xenograft models of triple-negative breast cancer.
Contraindications
6 documented side effects by frequency
No community discussions found for SACITUZUMAB GOVITECAN yet.
0 available comparisons
No comparisons yet.
Dosage Forms
Tablet
Route
Intravenous